Editing Episodic memory (section)

==Pharmacological enhancement==
In healthy adults, longterm visual episodic memory can be enhanced specifically<ref>{{cite journal | vauthors = Grön G, Kirstein M, Thielscher A, Riepe MW, Spitzer M | title = Cholinergic enhancement of episodic memory in healthy young adults | journal = Psychopharmacology | volume = 182 | issue = 1 | pages = 170–9 | date = October 2005 | pmid = 16021483 | doi = 10.1007/s00213-005-0043-2 | s2cid = 21341306 }}</ref> through administration of the Acetylcholine esterase inhibitor [[Donepezil]], whereas verbal episodic memory can be improved in persons with the val/val genotype of the val158met polymorphism through administration of the CNS penetrant specific [[Catechol-O-methyl transferase|catecholamine-O-methyltransferase]] inhibitor [[Tolcapone]].<ref>{{cite journal | vauthors = Apud JA, Mattay V, Chen J, Kolachana BS, Callicott JH, Rasetti R, Alce G, Iudicello JE, Akbar N, Egan MF, Goldberg TE, Weinberger DR | title = Tolcapone improves cognition and cortical information processing in normal human subjects | journal = Neuropsychopharmacology | volume = 32 | issue = 5 | pages = 1011–20 | date = May 2007 | pmid = 17063156 | doi = 10.1038/sj.npp.1301227 | s2cid = 24026336 }}</ref> Furthermore, episodic memory is enhanced through [[Ispronicline|AZD3480]], a selective agonist at the neuronal alpha4beta2 nicotinic receptor, which is developed by the company Targacept.<ref>{{cite journal | vauthors = Dunbar G, Boeijinga PH, Demazières A, Cisterni C, Kuchibhatla R, Wesnes K, Luthringer R | title = Effects of TC-1734 (AZD3480), a selective neuronal nicotinic receptor agonist, on cognitive performance and the EEG of young healthy male volunteers | journal = Psychopharmacology | volume = 191 | issue = 4 | pages = 919–29 | date = May 2007 | pmid = 17225162 | doi = 10.1007/s00213-006-0675-x | s2cid = 10920515 }}</ref> Currently, there are several other products developed by several companies—including new catecholamine-O-methyltransferase inhibitors with fewer side effects—that aim for improving episodic memory. A recent placebo controlled study found that [[DHEA]], which is a functional cortisol antagonist, improves episodic memory in healthy young men (Alhaj et al. 2006).<ref>{{cite journal | vauthors = Alhaj HA, Massey AE, McAllister-Williams RH | title = Effects of DHEA administration on episodic memory, cortisol and mood in healthy young men: a double-blind, placebo-controlled study | journal = Psychopharmacology | volume = 188 | issue = 4 | pages = 541–51 | date = November 2006 | pmid = 16231168 | doi = 10.1007/s00213-005-0136-y | s2cid = 25964357 }}</ref>

A 2015 [[meta-analysis]] of high quality evidence found that therapeutic doses of [[amphetamine]] and [[methylphenidate]] improve performance on [[working memory]], episodic memory, and [[inhibitory control]] tests in normal healthy adults.<ref name="Cognitive and motivational effects">{{cite journal | vauthors = Ilieva IP, Hook CJ, Farah MJ | title = Prescription Stimulants' Effects on Healthy Inhibitory Control, Working Memory, and Episodic Memory: A Meta-analysis | journal = Journal of Cognitive Neuroscience | volume = 27 | issue = 6 | pages = 1069–89 | date = June 2015 | pmid = 25591060 | doi = 10.1162/jocn_a_00776 | s2cid = 15788121 | url = https://repository.upenn.edu/neuroethics_pubs/130 | url-access = subscription }}</ref>